Central Nervous System Infections in Heart Transplant Recipients
Arch Neurol 64:1715-1720, van de Beek,D.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Multifocal Motor Neuropathy: The Diagnostic Spectrum and Response to Treatment
Neurol 69:1680-1687, Slee,M.,et al, 2007
Parental Transmission of MS in a Population-Based Canadian Cohort
Neurol 69:1208-1212,1202, Herrera,B.M.,et al, 2007
Thalamic Atrophy and Cognition in Multiple Sclerosis
Neurol 69:1213-1223, Houtchens,M.K.,et al, 2007
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
The Incidence and Significance of Anti-Natalizumab Antibodies: Results from AFFIRM and SENTINEL
Neurol 69:1391-1403,1396, Calabresi,P.A.,et al, 2007
Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007
Quantitative Assessment of Iron Accumulation in the Deep Gray Matter of Multiple Sclerosis by Magnetic Field Correlation Imaging
AJNR 28:1639-1644, Ge,Y.,et al, 2007
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Arch Neurol 64:1426-1432, de Seze,J.,et al, 2007
Sarcoidosis: Clinical, Hormonal, and Magnetic Resonance Imaging (MRI) Manifestations of Hypothalamic-Pituitary Disease in 9 Patients and Review of the Literature
Medicine 86:259-268, Bihan,H.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Balos Concentric Sclerosis Presenting as a Stroke-Like Syndrome
Nat Clin Pract Neurol 3:349-354, Mowry,E.M.,et al, 2007
Multiple Sclerosis After Infectious Mononucleosis
Arch Neurol 64:72-75, Nielsen,T.R.,et al, 2007
Longitudinal Follow-Up of "Benign" Multiple Sclerosis at 20 Years
Neurol 68:496-500,480, Sayao,A-L.,et al, 2007
Neurosarcoidosis: A Treatable Cause of Vestibular Dysfunction
Lancet 369:878, Agari,D.,et al, 2007
Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS
Neurol 68:939-944, Cohen,J.A.,et a, 2007
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007
Aggressive Therapy for Neurosarcoidosis: Long-Term Follow-Up of 48 Treated Patients
Arch Neurol 64:691-696, Scott,T.F.,et al, 2007
Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia
Neurol 68:1630-1631, Cartwright,M.S.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007
Refractory Neurosarcoidosis Responsive to Infliximab
Pract Neurol 7:112-115, Kobylecki,C. &Shaunak,S., 2007
Natural History of Multiple Sclerosis with Childhood Onset
NEJM 356:2603-2613, Renoux,C.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Neuropsychiatric Syndromes Associated With Multiple Sclerosis
J Neurol 254:II/73-II/76, Feinstein,A., 2007
Inflammatory Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-Negative Patients
Ann Neurol 62:34-39, Huang,D.R.,et al, 2007
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007
Progressive Multifocal Leukoencephalopathy After Rituximab in a Case of Non-Hodgkin Lymphoma
Neurol 69:704-706, Kranick,S.M.,et al, 2007
Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007
What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
The Differential Diagnosis of Multiple Sclerosis
Neurologist 13:57-72, Rolak, L.A.,et al, 2007
Misdiagnosis of stroke
Expert Rev Neurother 7:989-1001, Nor, A.M.,et al, 2007
Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis
Mod Rheumatol 17-72-74, Yamamoto, M.,et al, 2007
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
JAMA 296:2832-2838, Munger,K.L.,et al, 2006
Multiple Sclerosis with and without CSF Bands:Clinically Indistinguishable but Immunogenetically Distinct
Neurol 67:1062-1064, Imrell,K.,et al, 2006
In Vivo Detection of Cortical Plaques by MR Imaging in Patients with Multiple Sclerosis
AJNR 27:2161-2167, Bagnato,F.,et al, 2006
Immune Reconstitution Inflammatory Syndrome Associated with PML in AIDS: A Treatable Disorder
Neurol 67:1692-1694, Martinez,J.V.,et al, 2006
Pathologic Laughing and Intractable Hiccups Can Occur Early in Multiple Sclerosis
Neurol 67:1684-1686, de Seze,J.,et al, 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006
Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006
Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006